{
  "trial_id": "NCT04125316",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Chinese subjects aged between 18 and 90 years",
      "label": "met"
    },
    {
      "criterion": "Have a diagnosis of asthma according to The Global Initiative for Asthma (GINA) guideline 2019.",
      "label": "met"
    },
    {
      "criterion": "Asthma is defined as those with a consistent history and prior documented evidence of variable airflow obstruction,",
      "label": "unknown"
    },
    {
      "criterion": "with evidence of an increase in FEV1 greater than 12% or 200 mL following bronchodilator or bronchial hyperresponsiveness on bronchial provocation testing, when stable.",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Patients with respiratory diseases with other known respiratory diseases including chronic obstructive pulmonary disease",
      "label": "not_met"
    },
    {
      "criterion": "Individuals older than 40 years with a smoking history of more than 10 pack-years",
      "label": "unknown"
    },
    {
      "criterion": "Patients currently randomized in other clinical studies",
      "label": "unknown"
    }
  ],
  "notes": "39-year-old man with cough and shortness of breath, diagnosed with asthma for 3 years. He uses inhaled corticosteroid (ICS) and fluticasone 500 mcg/salmeterol 50 mcg.",
  "_meta": {
    "topic_id": "23",
    "trial_id": "NCT04125316",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}